Effects Of Otago Exercise Versus Multisensory Integration Training On Balance And Gait In Elderly With Diabetes
Balance - DM
1 other identifier
interventional
90
1 country
1
Brief Summary
The goal of this clinical trial is to compare the effect of the Otago exercise and Multisensory integration training on balance and gait in the elderly with type 2 diabetes mellitus. The main question it aims to answer is:
- Is there a significant difference between the effect of Otago exercise and Multisensory integration training on balance and gait in the elderly with type 2 diabetes mellitus? Researchers will compare Otago exercise to Multisensory integration training to know which one has the greatest benefit on balance \&gait in the elderly with type2 diabetes. Participants will be divided into 3 groups; each group takes a certain training program for 8 weeks:
- First group: Otago exercise group plus conventional treatment for neuropathy.
- Second group: Multisensory integration training group plus conventional treatment for neuropathy.
- Third group: control group takes only conventional treatment for neuropathy.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started Oct 2026
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
August 9, 2026
CompletedFirst Posted
Study publicly available on registry
August 20, 2026
CompletedStudy Start
First participant enrolled
October 1, 2026
CompletedPrimary Completion
Last participant's last visit for primary outcome
October 1, 2027
ExpectedStudy Completion
Last participant's last visit for all outcomes
November 1, 2027
August 20, 2026
August 1, 2026
1 year
August 9, 2026
August 17, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (3)
Balance: ( Time up & go test )dual task
From enrollment to the end of treatment at 8 weeks
Balance: Berg Balance Scale
From enrollment to the end of the treatment at 8 weeks
Gait speed (10m walk test)
From enrollment to the end of the treatment at 8 weeks
Secondary Outcomes (3)
Functional reach test.
From enrollment to the end of treatment at 8 weeks
Modified fall efficacy scale
From enrollment to the end of treatment at 8 weeks
Toronto clinical neuropathy score
From enrollment to the end of treatment at 8 weeks
Study Arms (3)
Otago exercise group
ACTIVE COMPARATOROtago exercise plus conventional treatment for neuropathy. for 3d/w for 8weeks.
Multisensory integration training group
ACTIVE COMPARATORMultisensory integration training group with conventional treatment for neuropathy. for 3d/w for 8 weeks.
control group
ACTIVE COMPARATOROnly conventional treatment for neuropathy For 3d/w for 8 weeks.
Interventions
Exercise program consisted of ( flexibilty - strengthening - balance ) exercise for elderly. Time of each session (50:60 min). For 3d/w for 8weeks.
Multisensory integration training is a group of balance exercise depend on facilitating different sensory systems (visual-vestibular-propioception) Time for each session (50 min). For 3d/w for 8weeks.
conventional treatment for improving balance and gait problem associated with DPN For 3d/w for 8weeks
Eligibility Criteria
You may qualify if:
- Ninety elderly Patients of both genders.
- Their age will range from 65 to 75th.
- They will be diagnosed with type 2 diabetes for 5 years or more.
- Patients with mild \& moderate neuropathy will be included. (Based on the Toronto scale: -mild (6-8); moderate (9-11)
- Berg balance between (21 to \<50) patients with mild \&moderate risk of fall .
- Time up \& go dual task: patient takes longer than 10 sec.
- HBA1C for these patients was ≥ 6.5% .
- BMI will range from (18: 29,9 kg/m2).
- Able to walk independently, with or without assistive devices.
You may not qualify if:
- Any musculoskeletal disorder affecting the lower limb (fracture of the lower limb, tumors, any infection, ligament injuries, foot injuries).
- Any other neurological disorder influences gait such as (stroke, Parkinson's disease, cerebellar dysfunction, ataxia, vestibular disorders)
- Any other cardiovascular disease (arrhythmia, cardiac pacemakers).
- Unstable proliferative retinopathy and visual impairments without correction.
- Non-diabetic neuropathy (inflammatory, autoimmune disease, infections, tumors, vitamin B12 deficiency, hypothyroidism, alcoholism, injury or pressure on the nerve).
- The use of medications significantly impacting postural control (e.g., sedatives).
- Vestibular system and Cognitive disorders.
- Uncontrolled hypertension.
- Common peroneal nerve injury.
- Orthostatic hypotension.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Cairo Universitylead
Study Sites (1)
El-Qenayat Central Hospital
Zagazig, Egypt
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Gehad Ali Abd-Elhasseb, Assistant Professor
Cairo University
- PRINCIPAL INVESTIGATOR
Fatma Younis Mahmoud Abd-Elsalam, Lecturer of Physical Therapy
Cairo University
- PRINCIPAL INVESTIGATOR
Eman Mohamed El-Sayed Deif, consultant internal medicine
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- PARTICIPANT
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- physiotherapist
Study Record Dates
First Submitted
August 9, 2026
First Posted
August 20, 2026
Study Start
October 1, 2026
Primary Completion (Estimated)
October 1, 2027
Study Completion (Estimated)
November 1, 2027
Last Updated
August 20, 2026
Record last verified: 2026-08